Mechanisms of prostate cancer initiation and progression.

Prostate cancer is a major health problem as it continues to be the most frequently diagnosed cancer in men in the Western world. While improved early detection significantly decreased mortality, prostate cancer still remains the second leading cause of cancer-related death in Western men. Understanding the mechanisms of prostate cancer initiation and progression should have a significant impact on development of novel therapeutic approaches that can help to combat this disease. The recent explosion of novel high-throughput genetic technologies together with studies in animal models and human tissues allowed a comprehensive analysis and functional validation of the molecular changes. This chapter will summarize and discuss recently identified critical genetic and epigenetic changes that drive prostate cancer initiation and progression. These discoveries should help concentrate the efforts of drug development on key pathways and molecules, and finally translate the knowledge that is gained from mechanistic studies into effective treatments.

[1]  Paul D. P. Pharoah,et al.  p53 polymorphisms: cancer implications , 2009, Nature Reviews Cancer.

[2]  H. Grönberg,et al.  Estrogen Receptor β Polymorphism Is Associated with Prostate Cancer Risk , 2006, Clinical Cancer Research.

[3]  H. Freeze,et al.  Uncoupling of chondroitin sulfate glycosaminoglycan synthesis by brefeldin A , 1991, The Journal of cell biology.

[4]  A. Skubitz,et al.  Coordinate role for cell surface chondroitin sulfate proteoglycan and alpha 4 beta 1 integrin in mediating melanoma cell adhesion to fibronectin , 1992, The Journal of cell biology.

[5]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[6]  Evgeny N. Imyanitov,et al.  Gene polymorphisms, apoptotic capacity and cancer risk , 2009, Human Genetics.

[7]  I. Bernstein,et al.  The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23. , 1996, Blood.

[8]  P. Nelson,et al.  A causal role for ERG in neoplastic transformation of prostate epithelium , 2008, Proceedings of the National Academy of Sciences.

[9]  L. Terracciano,et al.  Clinicopathological and protein characterization of BRAF‐ and K‐RAS‐mutated colorectal cancer and implications for prognosis , 2010, International journal of cancer.

[10]  M. King,et al.  Genetic Heterogeneity in Human Disease , 2010, Cell.

[11]  Christopher I Amos,et al.  The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. , 2008, Journal of the National Cancer Institute.

[12]  M. Schön,et al.  Expression of the human alpha2 integrin subunit in mouse melanoma cells confers the ability to undergo collagen-directed adhesion, migration and matrix reorganization. , 1996, The Journal of investigative dermatology.

[13]  C. Boland,et al.  De novo constitutional MLH1 epimutations confer early‐onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one , 2011, International journal of cancer.

[14]  Jian Hui Wu,et al.  The androgen receptor gene mutations database (ARDB): 2004 update , 2004, Human mutation.

[15]  J. Carpten,et al.  A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with late-onset disease. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  E. Hurt,et al.  Effects of Manganese Superoxide Dismutase Silencing on Androgen Receptor Function and Gene Regulation: Implications for Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[17]  K. Foon,et al.  Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. , 1985, Cancer research.

[18]  F. Canzian,et al.  Is there still a need for candidate gene approaches in the era of genome-wide association studies? , 2009, Genomics.

[19]  M. O'brien,et al.  Comparison of Microsatellite Instability, CpG Island Methylation Phenotype, BRAF and KRAS Status in Serrated Polyps and Traditional Adenomas Indicates Separate Pathways to Distinct Colorectal Carcinoma End Points , 2006, The American journal of surgical pathology.

[20]  B. Uzzan,et al.  Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. , 2009, European journal of cancer.

[21]  W. Hahn,et al.  Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. , 2009, Journal of the National Cancer Institute.

[22]  P. Chaurand,et al.  A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. , 2001, Cancer research.

[23]  Ali Amin Al Olama,et al.  Multiple newly identified loci associated with prostate cancer susceptibility , 2008, Nature Genetics.

[24]  S. Ferrone,et al.  Targeting Melanoma Cells with Human High Molecular Weight-Melanoma Associated Antigen-Specific Antibodies Elicited by a Peptide Mimotope: Functional Effects , 2006, The Journal of Immunology.

[25]  J. Epstein,et al.  A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy. , 2009, Human pathology.

[26]  M. Augustus,et al.  Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. , 1997, Cancer research.

[27]  F. Roviello,et al.  Correlation of microsatellite instability at multiple loci with long-term survival in advanced gastric carcinoma. , 2009, Archives of surgery.

[28]  D. Ruiter,et al.  Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue. , 1991, The American journal of pathology.

[29]  U. Reinhold,et al.  Effects of diagnostic application of monoclonal antibody on survival in melanoma patients. , 1997, Hybridoma.

[30]  Suk Woo Nam,et al.  PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas , 2005, Oncogene.

[31]  C. Ambrosone,et al.  Molecular epidemiology to better predict lung cancer risk. , 2008, Clinical lung cancer.

[32]  Jeremy R. Jass,et al.  HNPCC and Sporadic MSI-H Colorectal Cancer: A Review of the Morphological Similarities and Differences , 2004, Familial Cancer.

[33]  K. Tomer,et al.  Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer , 2005, Clinical Cancer Research.

[34]  P. Nelson,et al.  Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis , 2008, British Journal of Cancer.

[35]  L. Hood,et al.  Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. , 1999, Cancer research.

[36]  D. Bostwick,et al.  Human prostate cancer risk factors , 2004, Cancer.

[37]  Zheng Qin.  Immunotherapy for melanoma:current status and perspectives , 2011 .

[38]  R. Mebius,et al.  High endothelial venules: lymphocyte traffic control and controlled traffic. , 1997, Advances in immunology.

[39]  D. Salter,et al.  Expression of NG2/human melanoma proteoglycan in human adult articular chondrocytes. , 1998, Osteoarthritis and cartilage.

[40]  W. Isaacs,et al.  Association of IL10 and Other immune response‐ and obesity‐related genes with prostate cancer in CLUE II , 2009, The Prostate.

[41]  Elisabeth Brambilla,et al.  Pathology and genetics of tumours of the lung , pleura, thymus and heart , 2004 .

[42]  M. Ohmuraya,et al.  Serine Protease Inhibitor Kazal Type 1 Promotes Proliferation of Pancreatic Cancer Cells through the Epidermal Growth Factor Receptor , 2009, Molecular Cancer Research.

[43]  V. Sondak,et al.  Melanoma: Adjuvant therapy and other treatment options , 2003, Current treatment options in oncology.

[44]  W. Stallcup,et al.  Participation of the NG2 proteoglycan in rat aortic smooth muscle cell responses to platelet-derived growth factor. , 1995, Experimental cell research.

[45]  Suet Yi Leung,et al.  Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1 , 2009, Nature Genetics.

[46]  L. Abrahmsén,et al.  Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma , 2000, Cancer Immunology, Immunotherapy.

[47]  R. Reisfeld,et al.  Inhibition of anchorage-independent growth of human melanoma cells by a monoclonal antibody to a chondroitin sulfate proteoglycan. , 1983, Journal of the National Cancer Institute.

[48]  Eugene Kim,et al.  Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men , 2002, The Prostate.

[49]  K. Shianna,et al.  A Genome-Wide Association Study in Chronic Obstructive Pulmonary Disease (COPD): Identification of Two Major Susceptibility Loci , 2009, PLoS genetics.

[50]  S. Veeramani,et al.  Mitochondrial redox signaling by p66Shc is involved in regulating androgenic growth stimulation of human prostate cancer cells , 2008, Oncogene.

[51]  Y. Wen,et al.  Molecular basis of interaction between NG2 proteoglycan and galectin‐3 , 2006, Journal of cellular biochemistry.

[52]  Z. Ye,et al.  Relationship between single nucleotide polymorphisms in −174G/C and −634C/G promoter region of interleukin-6 and prostate cancer , 2008, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban.

[53]  P. Møller,et al.  Germ-Line Mutations in Mismatch Repair Genes Associated with Prostate Cancer , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[54]  S. Pestka,et al.  Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells. , 1984, Journal of immunology.

[55]  E. Espin,et al.  BRAF mutations in colorectal carcinoma suggest two entities of microsatellite‐unstable tumors , 2006, Cancer.

[56]  S. Hayward,et al.  Stromal-epithelial interactions in the normal and neoplastic prostate. , 1997, British journal of urology.

[57]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[58]  C. Bieberich,et al.  Decreased NKX3.1 Protein Expression in Focal Prostatic Atrophy, Prostatic Intraepithelial Neoplasia, and Adenocarcinoma: Association with Gleason Score and Chromosome 8p Deletion , 2006 .

[59]  T. Rebbeck,et al.  Evaluation of prostate cancer characteristics in four populations worldwide. , 2008, The Canadian journal of urology.

[60]  Peter A. Humphrey,et al.  Conditional Loss of Nkx3.1 in Adult Mice Induces Prostatic Intraepithelial Neoplasia , 2002, Molecular and Cellular Biology.

[61]  S. J. Higgins,et al.  The endocrinology and developmental biology of the prostate. , 1987, Endocrine reviews.

[62]  Tony Pawson,et al.  Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer , 2004, Nature Genetics.

[63]  P. Carroll,et al.  Pathological outcomes of candidates for active surveillance of prostate cancer. , 2009, The Journal of urology.

[64]  L. Chung,et al.  Reactive oxygen species mediate androgen receptor‐ and serum starvation‐elicited downstream signaling of ADAM9 expression in human prostate cancer cells , 2007, The Prostate.

[65]  J. Yokota,et al.  Association of the OGG1‐Ser326Cys polymorphism with lung adenocarcinoma risk , 2006, Cancer science.

[66]  L. van der Merwe,et al.  COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men. , 2008, Carcinogenesis.

[67]  G. Cunha,et al.  Inability of Tfm (testicular feminization) epithelial cells to express androgen-dependent seminal vesicle secretory proteins in chimeric tissue recombinants. , 1991, Endocrinology.

[68]  J. Brooks,et al.  Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[69]  W. Stallcup,et al.  Interaction of the NG2 proteoglycan with the actin cytoskeleton , 1996, Journal of cellular biochemistry.

[70]  N. Matsubara,et al.  BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum , 2004, Gut.

[71]  A. Rustgi,et al.  The genetics of hereditary colon cancer. , 2007, Genes & development.

[72]  W. Stallcup,et al.  NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis , 2001, Developmental dynamics : an official publication of the American Association of Anatomists.

[73]  S. Ferrone,et al.  Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms , 2004, The Journal of cell biology.

[74]  A. Hauschild,et al.  Epidemiology of invasive cutaneous melanoma , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  G Dhom,et al.  Relation of endocrine‐paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate , 1991, The Prostate.

[76]  M. Shen,et al.  Progenitor cells for the prostate epithelium: roles in development, regeneration, and cancer. , 2008, Cold Spring Harbor symposia on quantitative biology.

[77]  E. Giovannucci,et al.  Role of diet in prostate cancer development and progression. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  Paolo Vineis,et al.  Sequence variants at the TERT-CLPTM1L locus associate with many cancer types , 2009, Nature Genetics.

[79]  V. Torri,et al.  Reduced Likelihood of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer , 2007, Clinical Cancer Research.

[80]  S. Schwartz,et al.  Frequent Ki-ras mutations in gastric tumors of the MSI phenotype. , 2003, Gastroenterology.

[81]  Teruhiko Yoshida,et al.  Extensive but hemiallelic methylation of the hMLH1 promoter region in early-onset sporadic colon cancers with microsatellite instability. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[82]  M. Shen,et al.  Pten inactivation and the emergence of androgen-independent prostate cancer. , 2007, Cancer research.

[83]  K. Nave,et al.  Interaction of Syntenin-1 and the NG2 Proteoglycan in Migratory Oligodendrocyte Precursor Cells* , 2008, Journal of Biological Chemistry.

[84]  B. Dörken,et al.  Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1 , 2000, Leukemia.

[85]  J. Epstein,et al.  Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. , 1999, The American journal of pathology.

[86]  G. Fields,et al.  CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes. , 1996, Molecular biology of the cell.

[87]  S. Varambally,et al.  Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. , 2008, Cancer research.

[88]  T. Stamey,et al.  Keratin immunoreactivity in the benign and neoplastic human prostate. , 1985, Cancer research.

[89]  R. Hayes,et al.  Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. , 2009, Carcinogenesis.

[90]  H. Bartsch,et al.  Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[91]  H. Rubin.  Synergistic mechanisms in carcinogenesis by polycyclic aromatic hydrocarbons and by tobacco smoke: a bio-historical perspective with updates. , 2001, Carcinogenesis.

[92]  F. Balaguer,et al.  Concepts in familial colorectal cancer: where do we stand and what is the future? , 2009, Gastroenterology.

[93]  J. Kyriakis,et al.  A Novel Role for Mixed Lineage Kinase 3 (MLK3) in B-Raf Activation and Cell proliferation , 2004, Cell cycle.

[94]  Hiroyuki Yamamoto,et al.  BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes , 2005, Oncogene.

[95]  Peter Kraft,et al.  Toll-like Receptor Signaling Pathway Variants and Prostate Cancer Mortality , 2009, Cancer Epidemiology Biomarkers & Prevention.

[96]  G. Cunha,et al.  Whole-mount autoradiography study of DNA synthetic activity during postnatal development and androgen-induced regeneration in the mouse prostate. , 1986, Biology of reproduction.

[97]  A. Schwartz,et al.  The molecular epidemiology of lung cancer. , 2006, Carcinogenesis.

[98]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[99]  M. Ittmann,et al.  Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. , 2008, Cancer research.

[100]  K. Leong,et al.  Generation of a prostate from a single adult stem cell , 2008, Nature.

[101]  J. Qin,et al.  Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. , 2004, Molecular cell.

[102]  D. Aswad,et al.  Regulation of transcription by a protein methyltransferase. , 1999, Science.

[103]  Caterina A M La Porta,et al.  Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. , 2007, European journal of cancer.

[105]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[106]  P. Dijke,et al.  ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF-β/Smad-induced growth arrest of prostate cells , 2006, Oncogene.

[107]  S. Larson,et al.  Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: preliminary experience. , 1985, Radiology.

[108]  Olfert Landt,et al.  Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis , 2000, Nature Genetics.

[109]  R. Silverman,et al.  Interferon action and apoptosis are defective in mice devoid of 2′,5′‐oligoadenylate‐dependent RNase L , 1997, The EMBO journal.

[110]  J. Jass.  Molecular heterogeneity of colorectal cancer: Implications for cancer control. , 2007, Surgical oncology.

[111]  G. Evans,et al.  Cell proliferation studies in the rat prostate: II. The effects of castration and androgen‐induced regeneration upon basal and secretory cell proliferation , 1987, The Prostate.

[112]  B. Leggett,et al.  Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer. , 2002, Cancer research.

[113]  C. Milstein,et al.  Optimism after much pessimism: what next? , 1999, Current opinion in immunology.

[114]  M. Stolte,et al.  Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer. , 2006, International journal of oncology.

[115]  J. Schalken,et al.  Demonstration of Intermediate Cells during Human Prostate Epithelial Differentiation In Situ and In Vitro Using Triple-Staining Confocal Scanning Microscopy , 2000, Laboratory Investigation.

[116]  S. Murata,et al.  Immunohistochemical study of NG2 chondroitin sulfate proteoglycan expression in the small and large intestines , 2006, Histochemistry and Cell Biology.

[117]  J. Yokota,et al.  Differential ability of polymorphic OGG1 proteins to suppress mutagenesis induced by 8-hydroxyguanine in human cell in vivo. , 2004, Carcinogenesis.

[118]  Mark H. Tuszynski,et al.  NG2 Is a Major Chondroitin Sulfate Proteoglycan Produced after Spinal Cord Injury and Is Expressed by Macrophages and Oligodendrocyte Progenitors , 2002, The Journal of Neuroscience.

[119]  G. Deng,et al.  BRAF Mutation Is Frequently Present in Sporadic Colorectal Cancer with Methylated hMLH1, But Not in Hereditary Nonpolyposis Colorectal Cancer , 2004, Clinical Cancer Research.

[120]  Mustafa Ozen,et al.  Global Gene Expression Analysis of Reactive Stroma in Prostate Cancer , 2009, Clinical Cancer Research.

[121]  T. Smyrk,et al.  Hereditary nonpolyposis colorectal cancer (Lynch syndromes I & II). Genetics, pathology, natural history, and cancer control, Part I. , 1991, Cancer genetics and cytogenetics.

[122]  R. Lothe,et al.  Sporadic gastric carcinomas with microsatellite instability display a particular clinicopathologic profile , 1995, International journal of cancer.

[123]  Donald P Bottaro,et al.  Grb2 signaling in cell motility and cancer. , 2008, Expert opinion on therapeutic targets.

[124]  M. Ginsberg,et al.  Integrin cytoplasmic domain-binding proteins. , 2000, Journal of cell science.

[125]  W. Willett,et al.  Vitamin D Receptor Polymorphisms and Breast Cancer Risk: Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium , 2009, Cancer Epidemiology Biomarkers & Prevention.

[126]  P. Hainaut,et al.  TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. , 2005, Cancer research.

[127]  Bingshu E. Chen,et al.  Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. , 2007, Carcinogenesis.

[128]  R. Govindan.  Lung cancer in never smokers: a new hot area of research. , 2010, The Lancet. Oncology.

[129]  A. D. De Marzo,et al.  Epigenetic alterations in human prostate cancers. , 2009, Endocrinology.

[130]  Shuji Ogino,et al.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.

[131]  H. Lou,et al.  Induction of AKR1C2 by Phase II Inducers: Identification of a Distal Consensus Antioxidant Response Element Regulated by NRF2 , 2006, Molecular Pharmacology.

[132]  G. Steinbach,et al.  Antigenic profile of human melanoma cells. Analysis with monoclonal antibodies to histocompatibility antigens and to melanoma‐associated antigens , 1983, Journal of cutaneous pathology.

[133]  W. Stallcup,et al.  A role for the NG2 proteoglycan in glioma progression , 2008, Cell adhesion & migration.

[134]  Jianfeng Xu,et al.  Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.

[135]  T. Oegema,et al.  A role of chondroitin sulfate glycosaminoglycan binding site in alpha4beta1 integrin-mediated melanoma cell adhesion. , 1998, The Journal of biological chemistry.

[136]  W. Willett,et al.  Multiple loci identified in a genome-wide association study of prostate cancer , 2008, Nature Genetics.

[137]  R. Cardiff,et al.  Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model. , 2005, Cancer research.

[138]  S. Ferrone,et al.  Association of high molecular weight melanoma-associated antigen expression in primary acral lentiginous melanoma lesions with poor prognosis. , 1993, Cancer research.

[139]  A. Vis,et al.  Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways , 2009, BJU international.

[140]  E. Thiel,et al.  Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10−/CD24−/CD65s+/CD15+ B-cell phenotype , 2003, Leukemia.

[141]  Shuji Ogino,et al.  Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer , 2005, Clinical Cancer Research.

[142]  Koichi Goto,et al.  Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes. , 2010, Carcinogenesis.

[143]  Simon Heath,et al.  Lung cancer susceptibility locus at 5p15.33 , 2008, Nature Genetics.

[144]  I. Bernstein,et al.  MLL gene rearrangement, cytogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia. , 1997, Blood.

[145]  L. Liotta,et al.  Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. , 1996, Cancer research.

[146]  A. Gazdar,et al.  Lung cancer in never smokers — a different disease , 2007, Nature Reviews Cancer.

[147]  R. Kittles,et al.  Sequence variation within the 5′ regulatory regions of the vitamin D binding protein and receptor genes and prostate cancer risk , 2005, The Prostate.

[148]  N. Camp,et al.  Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in ELAC2 (HPC2) and prostate cancer. , 2002, American journal of human genetics.

[149]  D. Bostwick,et al.  Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. , 1997, Cancer research.

[150]  Raquel Seruca,et al.  Helicobacter pylori infection generates genetic instability in gastric cells. , 2010, Biochimica et biophysica acta.

[151]  Justin C. Earp,et al.  Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies , 2009, Cancer Immunology, Immunotherapy.

[152]  M. Geletu,et al.  Beyond structure, to survival: activation of Stat3 by cadherin engagement. , 2009, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[153]  Darryl Shibata,et al.  Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis , 1993, Nature.

[154]  R. Timpl,et al.  Binding of the NG2 Proteoglycan to Type VI Collagen and Other Extracellular Matrix Molecules* , 1996, The Journal of Biological Chemistry.

[155]  Rameen Beroukhim,et al.  An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB , 2010, Nature Medicine.

[156]  K. Pienta,et al.  A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. , 2007, Molecular cell.

[157]  Hiroyuki Yamamoto,et al.  Differential involvement of the hypermethylator phenotype in hereditary and sporadic colorectal cancers with high‐frequency microsatellite instability , 2002, Genes, chromosomes & cancer.

[158]  M. Feldmann,et al.  Rac mediates TNF-induced cytokine production via modulation of NF-kappaB. , 2008, Molecular immunology.

[159]  C. Carlson,et al.  C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older , 2009, Cancer Causes & Control.

[160]  Hui-Yi Lin,et al.  Cytokine genetic polymorphisms and prostate cancer aggressiveness. , 2009, Carcinogenesis.

[161]  Hongbing Shen,et al.  Common genetic variants on 5p15.33 contribute to risk of lung adenocarcinoma in a Chinese population. , 2009, Carcinogenesis.

[162]  Zhiyong Guo,et al.  Regulation of androgen receptor activity by tyrosine phosphorylation. , 2006, Cancer cell.

[163]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[164]  L. Chung,et al.  Tumor-stroma co-evolution in prostate cancer progression and metastasis. , 2010, Seminars in cell & developmental biology.

[165]  R. Lefkowitz,et al.  New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades , 2001, Oncogene.

[166]  Å. Borg,et al.  Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer , 2010, Familial Cancer.

[167]  J. Carpten,et al.  Evidence for two independent prostate cancer risk–associated loci in the HNF1B gene at 17q12 , 2008, Nature Genetics.

[168]  R. Seruca,et al.  The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genes": a study of the TGFbeta RII, IGFII R, and BAX genes. , 1998, The American journal of pathology.

[169]  C. Mao,et al.  P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case–control studies , 2009, Human Genetics.

[170]  V. Agnese,et al.  Patterns of genomic instability in gastric cancer: clinical implications and perspectives. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[171]  C. Boland,et al.  Structure and function of the components of the human DNA mismatch repair system , 2006, International journal of cancer.

[172]  Inês Barroso,et al.  Meta-analysis and imputation refines the association of 15q25 with smoking quantity , 2010, Nature Genetics.

[173]  S. Ferrone,et al.  Differential Immunogenicity of Two Peptides Isolated by High Molecular Weight-Melanoma-Associated Antigen-Specific Monoclonal Antibodies with Different Affinities1 , 2005, The Journal of Immunology.

[174]  J. Witte,et al.  Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2 , 2004, European Journal of Human Genetics.

[175]  E. Gillanders,et al.  Analysis of HPC1, HPCX, and PCaP in Icelandic hereditary prostate cancer , 2000, Human Genetics.

[176]  S. Memarzadeh,et al.  Basal epithelial stem cells are efficient targets for prostate cancer initiation , 2010, Proceedings of the National Academy of Sciences.

[177]  S. Stevanović.  Identification of tumour-associated t-cell epitopes for vaccine development , 2002, Nature Reviews Cancer.

[178]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[179]  J. Jass.  Colorectal cancer: a multipathway disease. , 2006, Critical reviews in oncogenesis.

[180]  Clifford A. Meyer,et al.  Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer , 2009, Cell.

[181]  B. Wilson,et al.  Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy. , 2007, Neoplasia.

[182]  R. Karnes,et al.  Phenethyl isothiocyanate inhibits STAT3 activation in prostate cancer cells. , 2009, Molecular nutrition & food research.

[183]  K. Grigor,et al.  Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer , 2003, British Journal of Cancer.

[184]  J. Cerhan,et al.  No association of germline alteration of MSR1 with prostate cancer risk , 2003, Nature Genetics.

[185]  G. Coetzee,et al.  Genomic Androgen Receptor-Occupied Regions with Different Functions, Defined by Histone Acetylation, Coregulators and Transcriptional Capacity , 2008, PloS one.

[186]  Jun Luo,et al.  Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis , 2008, Modern Pathology.

[187]  C. Raftopoulos,et al.  Non-invasive measurement of intracranial pressure in the newborn and the infant: the Rotterdam teletransducer. , 1993, Archives of disease in childhood.

[188]  M. Agostini,et al.  Epidermal growth factor receptor (EGFR): mutational and protein expression analysis in gastric cancer. , 2006, Anticancer research.

[189]  J. Coxhead,et al.  Mutations in APC, Kirsten-ras, and p53—alternative genetic pathways to colorectal cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[190]  A. Borkhardt,et al.  Infant acute lymphoblastic leukemia – combined cytogenetic, immunophenotypical and molecular analysis of 77 cases , 2002, Leukemia.

[191]  P. Albertsen.  Treatment of localized prostate cancer: when is active surveillance appropriate? , 2010, Nature Reviews Clinical Oncology.

[192]  J. Mohler,et al.  Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation , 2007, Proceedings of the National Academy of Sciences.

[193]  J. Herman,et al.  Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia , 2001, Oncogene.

[194]  Shuping Zhao,et al.  Increased expression of stem cell markers in malignant melanoma , 2007, Modern Pathology.

[195]  J. Carpten,et al.  Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. , 2002, Cancer research.

[196]  D. Gudbjartsson,et al.  New common variants affecting susceptibility to basal cell carcinoma , 2009, Nature Genetics.

[197]  P. Peltomäki,et al.  DNA mismatch repair and cancer. , 2001, Mutation research.

[198]  R. Shah,et al.  Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression , 2009, Modern Pathology.

[199]  M. Ross,et al.  Fine Specificity of High Molecular Weight-Melanoma-Associated Antigen-Specific Cytotoxic T Lymphocytes Elicited by Anti-Idiotypic Monoclonal Antibodies in Patients with Melanoma , 2004, Cancer Research.

[200]  Tapio Visakorpi,et al.  Association of SPINK1 Expression and TMPRSS2:ERG Fusion with Prognosis in Endocrine-Treated Prostate Cancer , 2010, Clinical Cancer Research.

[201]  C. Sander,et al.  Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis , 2009, Nature Genetics.

[202]  G. Cunha.  The role of androgens in the epithelio‐mesenchymal interactions involved in prostatic morphogenesis in embryonic mice , 1973, The Anatomical record.

[203]  John Trachtenberg,et al.  Variants of the hK2 Protein Gene (KLK2) Are Associated with Serum hK2 Levels and Predict the Presence of Prostate Cancer at Biopsy , 2006, Clinical Cancer Research.

[204]  F. Roviello,et al.  MSI phenotype and MMR alterations in familial and sporadic gastric cancer , 2011, International journal of cancer.

[205]  Stephen J Chanock,et al.  Genome-wide association studies in cancer--current and future directions. , 2010, Carcinogenesis.

[206]  P. Nelson,et al.  Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. , 2007, Cancer research.

[207]  Alexander Roesch,et al.  A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.

[208]  V. Bonham,et al.  Human difference in the genomic era: Facilitating a socially responsible dialogue , 2010, BMC Medical Genomics.

[209]  D. Ornstein,et al.  Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium. , 2001, The Journal of urology.

[210]  P. Lian,et al.  Clinicopathologic and molecular features of sporadic microsatellite- and chromosomal-stable colorectal cancers , 2008, International Journal of Colorectal Disease.

[211]  J. Abraham,et al.  Circulating tumor cells in the management of breast cancer. , 2010, Clinical breast cancer.

[212]  S. Schwartz,et al.  The prevalence of PIK3CA mutations in gastric and colon cancer. , 2005, European journal of cancer.

[213]  B. Morris,et al.  hOGG1 Ser326Cys polymorphism and lung cancer susceptibility. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[214]  E. Petricoin,et al.  Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. , 2005, The Journal of clinical investigation.

[215]  C. Maier,et al.  Germline mutations of the MSR1 gene in prostate cancer families from Germany , 2006, Human mutation.

[216]  John D Potter,et al.  Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. , 2008, JAMA.

[217]  P. Nelson,et al.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.

[218]  John T. Wei,et al.  The role of SPINK1 in ETS rearrangement-negative prostate cancers. , 2008, Cancer cell.

[219]  S. Ferrone,et al.  Antigenic profile of mucosal melanoma lesions , 1994, International journal of cancer.

[220]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[221]  Andrew J. Vickers,et al.  Blood Biomarker Levels to Aid Discovery of Cancer-Related Single-Nucleotide Polymorphisms: Kallikreins and Prostate Cancer , 2010, Cancer Prevention Research.

[222]  W. Barry,et al.  CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. , 2010, Journal of the National Cancer Institute.

[223]  J. Carpten,et al.  Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. , 2009, Human molecular genetics.

[224]  M. Götte,et al.  Functions of cell surface heparan sulfate proteoglycans. , 1999, Annual review of biochemistry.

[225]  R. Figlin,et al.  STAT3: a target to enhance antitumor immune response. , 2011, Current topics in microbiology and immunology.

[226]  P. Itin,et al.  Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[227]  Sharon J. Diskin,et al.  Copy number variation at 1q21.1 associated with neuroblastoma , 2009, Nature.

[228]  R. Seruca,et al.  Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. , 1996, Gastroenterology.

[229]  P. Kantoff,et al.  Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[230]  S. Heath,et al.  Association between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17 000 individuals. , 2010, International journal of epidemiology.

[231]  H. Nagawa,et al.  Left‐Sided microsatellite unstable colorectal cancers show less frequent methylation of hMLH1 and CpG island methylator phenotype than right‐sided ones , 2007 .

[232]  M. Ittmann,et al.  Interleukin-6 is an autocrine growth factor in human prostate cancer. , 2001, The American journal of pathology.

[233]  R. Vessella,et al.  Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.

[234]  J. O'Connell,et al.  Human progelatinase A can be activated by matrilysin , 1994, FEBS letters.

[235]  David I. K. Martin,et al.  Germline epimutation of MLH1 in individuals with multiple cancers , 2004, Nature Genetics.

[236]  M. Spitz,et al.  Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. , 2009, Cancer research.

[237]  H. Bonkhoff,et al.  Basement membranes in fetal, adult normal, hyperplastic and neoplastic human prostate , 2005, Virchows Archiv A.

[238]  J. Yokota,et al.  Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA , 1998, Oncogene.

[239]  I. Bernstein,et al.  Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. , 1996, Blood.

[240]  Y. Inoue,et al.  The expression of human high molecular weight melanoma-associated antigen in acral lentiginous melanoma. , 2010, Bioscience trends.

[241]  D. Ruiter,et al.  Heterogeneous expression of melanoma-associated antigens in uveal melanomas. , 1987, Current eye research.

[242]  C. Verfaillie,et al.  Activation of β1 integrins on CML progenitors reveals cooperation between β1 integrins and CD44 in the regulation of adhesion and proliferation , 1997, Leukemia.

[243]  J. Iida,et al.  Spreading and focal contact formation of human melanoma cells in response to the stimulation of both melanoma-associated proteoglycan (NG2) and alpha 4 beta 1 integrin. , 1995, Cancer research.

[244]  Pär Stattin,et al.  Cumulative association of five genetic variants with prostate cancer. , 2008, The New England journal of medicine.

[245]  S. Schwartz,et al.  Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation , 2004, Genes, chromosomes & cancer.

[246]  Zhifu Sun,et al.  Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. , 2010, The Lancet. Oncology.

[247]  S. Ferrone,et al.  Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. , 1994, Cancer research.

[248]  M. Terris,et al.  The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: results from the Shared Equal Access Regional Cancer Hospital Database , 2008, BJU International.

[249]  H. Klocker,et al.  Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. , 1998, Cancer research.

[250]  L. Borsu,et al.  Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. , 2009, Cancer research.

[251]  Antoni Ribas,et al.  Current developments in cancer vaccines and cellular immunotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[252]  B. Uzzan,et al.  Microsatellite instability: a predictive marker in metastatic colorectal cancer? , 2009, Targeted Oncology.

[253]  S. Ferrone,et al.  Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. , 2008, Cancer research.

[254]  A. Goel,et al.  Role of hMLH1 promoter hypermethylation in drug resistance to 5‐fluorouracil in colorectal cancer cell lines , 2003, International journal of cancer.

[255]  P. Peltomäki,et al.  Mutations Associated with HNPCC Predisposition — Update of ICG-HNPCC/INSiGHT Mutation Database , 2004, Disease markers.

[256]  R. Eils,et al.  Systemic spread is an early step in breast cancer. , 2008, Cancer cell.

[257]  W. Ellis,et al.  Disseminated Tumor Cells in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease Predicts Biochemical Recurrence , 2009, Clinical Cancer Research.

[258]  J. Subramanian,et al.  Molecular genetics of lung cancer in people who have never smoked. , 2008, The Lancet. Oncology.

[259]  J. Epstein.  An update of the Gleason grading system. , 2010, The Journal of urology.

[260]  F. Collins,et al.  Genomic medicine--an updated primer. , 2010, The New England journal of medicine.

[261]  P. Carroll,et al.  Multigene Methylation Analysis for Detection and Staging of Prostate Cancer , 2005, Clinical Cancer Research.

[262]  David A. Cheresh,et al.  Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin , 2007, Nature.

[263]  R. Nagle,et al.  Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. , 1987, Cancer research.

[264]  T. H. van der Kwast,et al.  High‐resolution array CGH identifies novel regions of genomic alteration in intermediate‐risk prostate cancer , 2009, The Prostate.

[265]  S. Larson,et al.  Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[266]  X. Wang,et al.  CSPG4 in cancer: multiple roles. , 2010, Current molecular medicine.

[267]  C. Behling,et al.  Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. , 2004, Gastroenterology.

[268]  Liang Xia,et al.  Functional analysis of 44 mutant androgen receptors from human prostate cancer. , 2002, Cancer research.

[269]  Karen Billeci,et al.  Hepsin activates pro‐hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor‐1B (HAI‐1B) and HAI‐2 , 2005, FEBS letters.

[270]  R. Wolff,et al.  APC Mutations and Other Genetic and Epigenetic Changes in Colon Cancer , 2007, Molecular Cancer Research.

[271]  H. Scher,et al.  Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. , 2009, The Lancet. Oncology.

[272]  R. Cardiff,et al.  Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. , 2003, Cancer research.

[273]  H. Grönberg,et al.  Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development. , 2006, Cancer research.

[274]  S. Ferrone,et al.  Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. , 2005, The Journal of investigative dermatology.

[275]  E. Gelmann,et al.  R E V Ie W a Rt I C L E , 2022 .

[276]  G. Cunha,et al.  Morphogenesis of ductal networks in the mouse prostate. , 1986, Biology of reproduction.

[277]  T. Jenuwein,et al.  Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression , 2007, Nature Cell Biology.

[278]  S. Dhanasekaran,et al.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.

[279]  C. Allis,et al.  Methylation of Histone H4 at Arginine 3 Facilitating Transcriptional Activation by Nuclear Hormone Receptor , 2001, Science.

[280]  C. Gieger,et al.  Sequence variants at CHRNB3–CHRNA6 and CYP2A6 affect smoking behavior , 2010, Nature Genetics.

[281]  R. Schwall,et al.  Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. , 2002, Cancer research.

[282]  L. Hermo,et al.  Unique features of the basal cells of human prostate epithelium , 2000, Microscopy research and technique.

[283]  W. Stallcup.  The NG2 proteoglycan: Past insights and future prospects , 2002, Journal of neurocytology.

[284]  T. Sun,et al.  Proximal location of mouse prostate epithelial stem cells , 2002, The Journal of cell biology.

[285]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[286]  I. Thompson,et al.  Single and Multigenic Analysis of the Association between Variants in 12 Steroid Hormone Metabolism Genes and Risk of Prostate Cancer , 2009, Cancer Epidemiology Biomarkers & Prevention.

[287]  M. Salto‐Tellez,et al.  Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. , 2008, European journal of cancer.

[288]  D. Altshuler,et al.  Sequence Variants of Estrogen Receptor β and Risk of Prostate Cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium , 2007, Cancer Epidemiology Biomarkers & Prevention.

[289]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[290]  A. Waseem,et al.  Changes in the expression of stem cell markers in oral lichen planus and hyperkeratotic lesions. , 2007, Journal of oral science.

[291]  Dante diTommaso,et al.  Quantifying the role of PSA screening in the US prostate cancer mortality decline , 2008, Cancer Causes & Control.

[292]  P. Picci,et al.  NG2 expression predicts the metastasis formation in soft‐tissue sarcoma patients , 2009, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[293]  G. Rassner,et al.  Immunomagnetic Enrichment, Genomic Characterization, and Prognostic Impact of Circulating Melanoma Cells , 2004, Clinical Cancer Research.

[294]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[295]  S. Rosenberg,et al.  Adoptive cell therapy for the treatment of patients with metastatic melanoma. , 2009, Current opinion in immunology.

[296]  M. Lark,et al.  The melanoma proteoglycan: restricted expression on microspikes, a specific microdomain of the cell surface , 1986, The Journal of cell biology.

[297]  C Roland Wolf,et al.  Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of nrf2 by cancer chemotherapeutic agents. , 2006, Cancer research.

[298]  M. O'brien.  Hyperplastic and serrated polyps of the colorectum. , 2007, Gastroenterology clinics of North America.

[299]  J. Jass.  Serrated adenoma of the colorectum and the DNA-methylator phenotype , 2005, Nature Clinical Practice Oncology.

[300]  Shunyou Wang,et al.  Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[301]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[302]  G van den Engh,et al.  Cell-cell interaction in prostate gene regulation and cytodifferentiation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[303]  Michael Ittmann,et al.  Mutation of the androgen receptor causes oncogenic transformation of the prostate. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[304]  G. Wilson,et al.  Efficient in vivo targeting of malignant melanoma by single-chain Fv antibody fragments. , 1999, Melanoma research.

[305]  G. Prins,et al.  Molecular signaling pathways that regulate prostate gland development. , 2008, Differentiation; research in biological diversity.

[306]  J. Carpten,et al.  Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk , 2002, Nature Genetics.

[307]  John P A Ioannidis,et al.  A compendium of genome-wide associations for cancer: critical synopsis and reappraisal. , 2010, Journal of the National Cancer Institute.

[308]  T Ochiya,et al.  PDGF (alpha)-receptor is unresponsive to PDGF-AA in aortic smooth muscle cells from the NG2 knockout mouse. , 1999, Journal of cell science.

[309]  R. Shah,et al.  Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.

[310]  J. Jiricny.  The multifaceted mismatch-repair system , 2006, Nature Reviews Molecular Cell Biology.

[311]  Hiroyuki Yamamoto,et al.  Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. , 2008, Carcinogenesis.

[312]  K. Scheidtmann,et al.  Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation , 2008, Nature Cell Biology.

[313]  R. V. van Breemen,et al.  Multitargeted therapy of cancer by lycopene. , 2008, Cancer letters.

[314]  J. Derisi,et al.  Identification of a Novel Gammaretrovirus in Prostate Tumors of Patients Homozygous for R462Q RNASEL Variant , 2006, PLoS pathogens.

[315]  L. Aaltonen,et al.  BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing , 2004, Journal of Medical Genetics.

[316]  S. Fletcher,et al.  Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. , 2009, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[317]  Marshall W. Anderson,et al.  Fine Mapping of Chromosome 6q23-25 Region in Familial Lung Cancer Families Reveals RGS17 as a Likely Candidate Gene , 2009, Clinical Cancer Research.

[318]  Zhiyong Guo,et al.  A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. , 2009, Cancer research.

[319]  E. Bertini,et al.  Human melanoma/NG2 chondroitin sulfate proteoglycan is expressed in the sarcolemma of postnatal human skeletal myofibers Abnormal expression in merosin-negative and Duchenne muscular dystrophies , 2003, Molecular and Cellular Neuroscience.

[320]  S. Ferrone,et al.  Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[321]  B. Becher,et al.  Expression of a homologue of rat NG2 on human microglia , 1999, Glia.

[322]  Tapio Visakorpi,et al.  The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late‐stage prostate cancer , 2006, Genes, chromosomes & cancer.

[323]  R. Silverman,et al.  Small self-RNA generated by RNase L amplifies antiviral innate immunity , 2007, Nature.

[324]  D. Hunter,et al.  Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. , 2005, Cancer research.

[325]  S. Ferrone,et al.  Higher cytolytic efficiency of an IgG2 alpha than of an IgG1 monoclonal antibody reacting with the same (or spatially close) determinant on a human high-molecular-weight melanoma-associated antigen. , 1982, Cellular immunology.

[326]  P. Black,et al.  Metastasis and angiogenesis. , 2004, Cancer treatment and research.

[327]  K. Cooney,et al.  Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF‐1, and IGFBP‐3 and prostate cancer risk in African‐American men: The Flint Men's Health Study , 2008, The Prostate.

[328]  H. Fujii,et al.  Expression of epidermal growth factor receptor in gastric carcinomas. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[329]  M. Becich,et al.  Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. , 2008, The Journal of urology.

[330]  B. Leggett,et al.  Methylation patterns define two types of hyperplastic polyp associated with colorectal cancer , 2004, Gut.

[331]  H. Bonkhoff,et al.  Distribution of basement membranes in primary and metastatic carcinomas of the prostate. , 1992, Human pathology.

[332]  Michael D. Cole,et al.  Upregulation of c-MYC in cis through a Large Chromatin Loop Linked to a Cancer Risk-Associated Single-Nucleotide Polymorphism in Colorectal Cancer Cells , 2010, Molecular and Cellular Biology.

[333]  David E. Williams,et al.  Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. , 2010, Cancer cell.

[334]  J. Rosen,et al.  Metastatic prostate cancer in a transgenic mouse. , 1996, Cancer research.

[335]  W. Stallcup,et al.  High-affinity Binding of Basic Fibroblast Growth Factor and Platelet-derived Growth Factor-AA to the Core Protein of the NG2 Proteoglycan* , 1999, The Journal of Biological Chemistry.

[336]  M. Ghesani,et al.  Carcinoembryonic Antigen (CEA) Scan in the Diagnosis of Recurrent Colorectal Carcinoma in a Patient with Increasing CEA Levels and Inconclusive Computed Tomographic Findings , 2003, Clinical nuclear medicine.

[337]  Esko Ukkonen,et al.  The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling , 2009, Nature Genetics.

[338]  C. Klein,et al.  Parallel progression of primary tumours and metastases , 2009, Nature Reviews Cancer.

[339]  I. Thompson,et al.  Chemoprevention of prostate cancer: agents and study designs. , 2007, The Journal of urology.

[340]  Zhaohui S. Qin,et al.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.

[341]  S. Dhanasekaran,et al.  Repression of E-cadherin by the polycomb group protein EZH2 in cancer , 2008, Oncogene.

[342]  B. Uzzan,et al.  Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. , 2009, Anticancer research.

[343]  I. Thompson,et al.  Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. , 2006, The Journal of urology.

[344]  Soldano Ferrone,et al.  Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[345]  J. Cooper.  Radiation therapy of malignant melanoma. , 2002, Dermatologic clinics.

[346]  K. Nave,et al.  The AN2 Protein Is a Novel Marker for the Schwann Cell Lineage Expressed by Immature and Nonmyelinating Schwann Cells , 2001, The Journal of Neuroscience.

[347]  D. Morton,et al.  mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. , 2009, Clinical chemistry.

[348]  Kari Stefansson,et al.  Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility , 2009, Nature Genetics.

[349]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[350]  I. Thompson,et al.  Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: Results from the prostate cancer prevention trial , 2010, The Prostate.

[351]  M. Moyad.  Soy, disease prevention, and prostate cancer. , 1999, Seminars in urologic oncology.

[352]  F. Cramer.  Somatic mutations , 1978, Nature.

[353]  J. Herman,et al.  Association between CpG island methylation and microsatellite instability in colorectal cancer. , 1997, Cancer research.

[354]  Paolo Vineis,et al.  A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25 , 2008, Nature.

[355]  J. Ajani,et al.  Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[356]  L. Aaltonen,et al.  The role of hypermethylation of thehMLH1 promoter region in HNPCC versus MSI+ sporadic colorectal cancers , 2000, Journal of medical genetics.

[357]  K. Flaherty,et al.  Mutation-driven drug development in melanoma , 2010, Current opinion in oncology.

[358]  D. Tindall,et al.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.

[359]  S. Tsugane,et al.  Cigarette smoking and subsequent risk of lung cancer by histologic type in middle‐aged Japanese men and women: The JPHC study , 2002, International journal of cancer.

[360]  M. Ross,et al.  Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[361]  S. Weed,et al.  Cortactin: coupling membrane dynamics to cortical actin assembly , 2001, Oncogene.

[362]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[363]  T. Mustelin,et al.  Differential phosphorylation of NG2 proteoglycan by ERK and PKCα helps balance cell proliferation and migration , 2007, The Journal of cell biology.

[364]  G. Opdenakker,et al.  Matrix Metalloproteinase-9 Facilitates Remyelination in Part by Processing the Inhibitory NG2 Proteoglycan , 2003, The Journal of Neuroscience.

[365]  W. Stallcup,et al.  Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells , 1998, Journal of cellular physiology.

[366]  L. Lim,et al.  Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas , 1999, Nature Cell Biology.

[367]  D. Bostwick,et al.  Determination of a minimal deletion interval on chromosome band 8p21 in sporadic prostate cancer † , 2002, Genes, chromosomes & cancer.

[368]  G. Moore,et al.  Immunotherapy of malignant disease. , 1969, Archives of surgery.

[369]  M. Shen,et al.  A luminal epithelial stem cell that is a cell of origin for prostate cancer , 2009, Nature.

[370]  D. Chang,et al.  Difference Between Proximal and Distal Microsatellite-Unstable Sporadic Colorectal Cancers: Analysis of Clinicopathological and Molecular Features and Prognoses , 2010, Annals of Surgical Oncology.

[371]  Robert Schlaberg,et al.  XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors , 2009, Proceedings of the National Academy of Sciences.

[372]  H. Pehamberger,et al.  Reduction of Human Melanoma Tumor Growth in Severe Combined Immunodeficient Mice by Passive Transfer of Antibodies Induced by a High Molecular Weight Melanoma-Associated Antigen Mimotope Vaccine , 2008, Clinical Cancer Research.

[373]  S. Ferrone,et al.  Suppression of human melanoma growth in nude mice injected with anti high-molecular-weight melanoma-associated antigen monoclonal antibody 225.28S conjugated to purothionin. , 1985, Japanese journal of cancer research : Gann.

[374]  J. Iida,et al.  Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion. , 1996, Seminars in cancer biology.

[375]  I. Leigh,et al.  Epidermal and hair follicle progenitor cells express melanoma-associated chondroitin sulfate proteoglycan core protein. , 2004, The Journal of investigative dermatology.

[376]  M. Rubin,et al.  Current thoughts on the role of the androgen receptor and prostate cancer progression. , 2005, Advances in anatomic pathology.

[377]  Katri Pylkäs,et al.  A recurrent mutation in PALB2 in Finnish cancer families , 2007, Nature.

[378]  J. Humm,et al.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.

[379]  Louis M. Weiner,et al.  Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.

[380]  M. Herlyn,et al.  Isolation and chemical characterization of a melanoma-associated proteoglycan antigen. , 1983, Archives of biochemistry and biophysics.

[381]  M. Sy,et al.  A cysteine residue located in the transmembrane domain of CD44 is important in binding of CD44 to hyaluronic acid , 1996, The Journal of experimental medicine.

[382]  M. Maio,et al.  Differential modulation by tumor necrosis factor and immune interferon of HLA class‐II antigens expressed by melanoma cells , 1989, International journal of cancer.

[383]  R. Reisfeld,et al.  Biosynthetic studies of proteoglycans in human melanoma cells with a monoclonal antibody to a core glycoprotein of chondroitin sulfate proteoglycans. , 1984, The Journal of biological chemistry.

[384]  Seth Falcon,et al.  Impact of PSA Screening on the Incidence of Advanced Stage Prostate Cancer in the United States: A Surveillance Modeling Approach , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

[385]  R Engers,et al.  Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation , 2004, British Journal of Cancer.

[386]  H. Hollema,et al.  Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome , 2009, Genes, chromosomes & cancer.

[387]  Paul Brennan,et al.  Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. , 2010, Journal of the National Cancer Institute.

[388]  R. Hamelin,et al.  BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis? , 2008, BMC Cancer.

[389]  John Quackenbush,et al.  Comprehensive Biostatistical Analysis of CpG Island Methylator Phenotype in Colorectal Cancer Using a Large Population-Based Sample , 2008, PloS one.

[390]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[391]  C. Townsend,et al.  Synthesis and antitumor activity of an inhibitor of fatty acid synthase , 2000 .

[392]  B. Foster,et al.  Growth factors as mediators of androgen action during the development of the male urogenital tract , 2004, World Journal of Urology.

[393]  R. Matusik,et al.  Characterization of cis elements of the probasin promoter necessary for prostate‐specific gene expression , 2010, The Prostate.

[394]  J. Céraline,et al.  Identification of novel truncated androgen receptor (AR) mutants including unreported pre‐mRNA splicing variants in the 22Rv1 hormone‐refractory prostate cancer (PCa) cell line , 2010, Human mutation.

[395]  Pier Paolo Pandolfi,et al.  Tenets of PTEN Tumor Suppression , 2008, Cell.

[396]  Minoru Toyota,et al.  Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer , 2007, Proceedings of the National Academy of Sciences.

[397]  J. Schalken,et al.  Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration , 1988, The Prostate.

[398]  K. Frazer,et al.  Human genetic variation and its contribution to complex traits , 2009, Nature Reviews Genetics.

[399]  M. Rubin,et al.  Genetic Variation of Genes Involved in Dihydrotestosterone Metabolism and the Risk of Prostate Cancer , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[400]  J. Kawamura,et al.  Morphological and functional heterogeneity in the rat prostatic gland. , 1991, Biology of reproduction.

[401]  S. Gruber,et al.  RNASEL mutations in hereditary prostate cancer , 2003, Journal of medical genetics.

[402]  J. Saldanha,et al.  MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer , 2009, BMC Cancer.

[403]  G. Cunha,et al.  Morphological and histological study of castration-induced degeneration and androgen-induced regeneration in the mouse prostate. , 1986, Biology of reproduction.

[404]  R. Scolyer,et al.  High molecular weight–melanoma‐associated antigen as a biomarker of desmoplastic melanoma , 2010, Pigment cell & melanoma research.

[405]  H. Scher,et al.  Targeting the androgen receptor pathway in prostate cancer. , 2008, Current opinion in pharmacology.

[406]  Muller Fabbri,et al.  Modulation of mismatch repair and genomic stability by miR-155 , 2010, Proceedings of the National Academy of Sciences.

[407]  Choung-Soo Kim,et al.  The association between Toll-like receptor 4 (TLR4) polymorphisms and the risk of prostate cancer in Korean men. , 2009, Cancer genetics and cytogenetics.

[408]  K. Kinzler,et al.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.

[409]  M. Shackleton,et al.  Progress in understanding melanoma propagation , 2010, Molecular oncology.

[410]  Elaine A. Ostrander,et al.  Multiple Novel Prostate Cancer Predisposition Loci Confirmed by an International Study: The PRACTICAL Consortium , 2008, Cancer Epidemiology Biomarkers & Prevention.

[411]  Dee W. West,et al.  Segregation analysis of prostate cancer in 1719 white, African-American and Asian-American families in the United States and Canada , 2002, Cancer Causes & Control.

[412]  M. Loda,et al.  CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies , 2006, Gut.

[413]  S. Beghelli,et al.  Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. , 2006, Surgery.

[414]  Bingshu E. Chen,et al.  TNF polymorphisms and prostate cancer risk , 2008, The Prostate.

[415]  Howard M. Einspahr,et al.  Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[416]  Randall G. Lee,et al.  Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator in colon cancer. , 2009, Archives of surgery.

[417]  S. Bull,et al.  Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. , 2000, The New England journal of medicine.

[418]  S. Ferrone,et al.  Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions. , 1991, Cancer research.

[419]  M. Sheetz,et al.  Cell migration by graded attachment to substrates and contraction. , 1994, Seminars in cell biology.

[420]  Clifford A. Meyer,et al.  FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription , 2008, Cell.

[421]  S. Ferrone,et al.  Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting , 2009, Journal of Neuro-Oncology.

[422]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[423]  Wen Tan,et al.  Genetic variants on chromosome 15q25 associated with lung cancer risk in Chinese populations. , 2009, Cancer research.

[424]  F. Collins,et al.  A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history , 2005, Journal of Medical Genetics.

[425]  C. Boland,et al.  Mismatch repair proficiency and in vitro response to 5-fluorouracil. , 1999, Gastroenterology.

[426]  Wei Zhang,et al.  The hOGG1 Ser326Cys Polymorphism and Lung Cancer Risk: A Meta-analysis , 2008, Cancer Epidemiology Biomarkers & Prevention.

[427]  W. Gerald,et al.  Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer , 2010, British Journal of Cancer.

[428]  S. Jakowlew.  Transforming growth factor-beta in cancer and metastasis. , 2006, Cancer metastasis reviews.

[429]  G. Johnson,et al.  Signalling: Mixed-lineage kinase control of JNK and p38 MAPK pathways , 2002, Nature Reviews Molecular Cell Biology.

[430]  J. Danesh,et al.  Methods and Findings , 2022 .

[431]  R. Hamelin,et al.  Concurrent hypermethylation of gene promoters is associated with a MSI-H phenotype and diploidy in gastric carcinomas. , 2003, European journal of cancer.

[432]  S. Abdulkadir,et al.  Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity , 2010, BMC Cancer.

[433]  M. Rubin,et al.  Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee , 2004, Cancer Research.

[434]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[435]  T. Mitchison.  Actin based motility on retraction fibers in mitotic PtK2 cells. , 1992, Cell motility and the cytoskeleton.

[436]  Harold Varmus,et al.  Seeding and Propagation of Untransformed Mouse Mammary Cells in the Lung , 2008, Science.

[437]  R. Ferris,et al.  Immunotherapy of Malignant Disease with Tumor Antigen–Specific Monoclonal Antibodies , 2009, Clinical Cancer Research.

[438]  A. Levine,et al.  A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans , 2007, Oncogene.

[439]  S. Kakar,et al.  Distinct CpG island methylation profiles and BRAF mutation status in serrated and adenomatous colorectal polyps , 2008, International journal of cancer.

[440]  R. Seruca,et al.  Bmc Cancer Epidermal Growth Factor Receptor Structural Alterations in Gastric Cancer , 2022 .

[441]  G. Schuler,et al.  Tumor-Reactive CD4+ T Cell Responses to the Melanoma-Associated Chondroitin Sulphate Proteoglycan in Melanoma Patients and Healthy Individuals in the Absence of Autoimmunity1 , 2007, The Journal of Immunology.

[442]  R. Santen,et al.  Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement , 1987, The Prostate.

[443]  Yi-dong Li,et al.  AN S296R MUTATION IN THE HUMAN ANDROGEN RECEPTOR CAUSES ACTIVATION OF THE RECEPTOR BY NON‐ANDROGENIC STEROIDS AND STRONGER INHIBITION BY THE NUCLEAR RECEPTOR COREPRESSOR N‐coR , 2008, Clinical and experimental pharmacology & physiology.

[444]  M. Madigan,et al.  Human uveal melanoma expresses NG2 immunoreactivity , 2003, The British journal of ophthalmology.

[445]  A. Duval,et al.  Genetic instability in human mismatch repair deficient cancers. , 2002, Annales de genetique.

[446]  S. Ferrone,et al.  Cross-reactivity of murine anti-human high molecular weight-melanoma associated antigen monoclonal antibodies with guinea pig melanoma cells. , 1987, Cancer research.

[447]  Bourquelot,et al.  NG2 expression in MLL rearranged acute myeloid leukaemia is restricted to monoblastic cases , 1999, British journal of haematology.

[448]  S. Schwartz,et al.  BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency , 2003, Oncogene.

[449]  S. Ferrone,et al.  Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 653.40S to human melanoma cells. , 1981, Journal of the National Cancer Institute.

[450]  J. Witte,et al.  8q24 and prostate cancer: association with advanced disease and meta-analysis , 2008, European Journal of Human Genetics.

[451]  Tsuey-Ming Chen,et al.  Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model , 2003, The Prostate.

[452]  L. Rasmussen,et al.  Helicobacter pylori Infection Induces Genetic Instability of Nuclear and Mitochondrial DNA in Gastric Cells , 2009, Clinical Cancer Research.

[453]  R. Seruca,et al.  BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAFV600E but not KRAS mutations , 2008, The Journal of pathology.

[454]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[455]  T. Sasaki,et al.  Structure and function of laminin LG modules. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[456]  S Ferrone,et al.  Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. , 1989, The American journal of pathology.

[457]  A. C. Yazici,et al.  Human bone marrow mesenchymal cells express NG2: possible increase in discriminative ability of flow cytometry during mesenchymal stromal cell identification. , 2009, Cytotherapy.

[458]  M. Herlyn,et al.  Immunochemical and functional analysis of HLA class II antigens induced by recombinant immune interferon on normal epidermal melanocytes. , 1987, Journal of immunology.

[459]  Megan Hitchins,et al.  MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer. , 2005, Gastroenterology.

[460]  D. Tindall,et al.  Androgen receptor structural and functional elements: role and regulation in prostate cancer. , 2007, Molecular endocrinology.

[461]  G. Bokoch.  Biology of the p21-activated kinases. , 2003, Annual review of biochemistry.

[462]  Michael F Clarke,et al.  The biology of cancer stem cells. , 2007, Annual review of cell and developmental biology.

[463]  M. Loda,et al.  A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. , 2002, Cancer research.

[464]  S. Hayward,et al.  Malignant transformation in a nontumorigenic human prostatic epithelial cell line. , 2001, Cancer research.

[465]  M. Sayegh,et al.  Regulation of Progenitor Cell Fusion by ABCB5 P-glycoprotein, a Novel Human ATP-binding Cassette Transporter* , 2003, Journal of Biological Chemistry.

[466]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[467]  R. Hofstra,et al.  MSI-L Gastric Carcinomas Share the hMLH1 Methylation Status of MSI-H Carcinomas but Not Their Clinicopathological Profile , 2000, Laboratory Investigation.

[468]  J. Epstein,et al.  Histology and cellular kinetics of prostatic atrophy. , 1998, The American journal of surgical pathology.

[469]  R. Vessella,et al.  In vivo Effects of the Human Type I Insulin-Like Growth Factor Receptor Antibody A12 on Androgen-Dependent and Androgen-Independent Xenograft Human Prostate Tumors , 2005, Clinical Cancer Research.

[470]  D. Arango,et al.  High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability , 2007, Oncogene.

[471]  M. Teitell,et al.  ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells , 2009, Proceedings of the National Academy of Sciences.

[472]  T. Mizuno,et al.  Induction of the rat prostate gland by androgens in organ culture. , 1977, The Journal of endocrinology.

[473]  C. Magi-Galluzzi,et al.  Can saturation biopsy predict prostate cancer localization in radical prostatectomy specimens: a correlative study and implications for focal therapy. , 2010, Urology.

[474]  A. Garner,et al.  Characterisation of ocular melanoma with cutaneous melanoma antibodies. , 1987, The British journal of ophthalmology.

[475]  Wei Zhao,et al.  Mutations of PIK3CA in gastric adenocarcinoma , 2005, BMC Cancer.

[476]  Daniel F. Gudbjartsson,et al.  A variant associated with nicotine dependence, lung cancer and peripheral arterial disease , 2008, Nature.

[477]  P. Broderick,et al.  Role of 5p15.33 (TERT-CLPTM1L), 6p21.33 and 15q25.1 (CHRNA5-CHRNA3) variation and lung cancer risk in never-smokers. , 2010, Carcinogenesis.

[478]  S. Simmons,et al.  Nkx3.1 binds and negatively regulates the transcriptional activity of Sp-family members in prostate-derived cells. , 2006, The Biochemical journal.

[479]  C. Damsky,et al.  FAK integrates growth-factor and integrin signals to promote cell migration , 2000, Nature Cell Biology.

[480]  B. Thiers,et al.  Identification of cells initiating human melanomas , 2009 .

[481]  R. Hofstra,et al.  Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer , 2005, Oncogene.

[482]  Brad Piche,et al.  Inhibitor of growth tumor suppressors in cancer progression , 2010, Cellular and Molecular Life Sciences.

[483]  H. Matsumoto,et al.  Mutations of the PIK3CA gene in hereditary colorectal cancers , 2007, International journal of cancer.

[484]  Sanjay Goel,et al.  An A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression. , 2009, Cancer research.

[485]  J. Trent,et al.  α-methylacyl-CoA racemase: A new molecular marker for prostate cancer , 2002 .

[486]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[487]  M. Lucia,et al.  Prostate Cancer Detected by Methylated Gene Markers in Histopathologically Cancer-Negative Tissues from Men with Subsequent Positive Biopsies , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[488]  H. Grönberg,et al.  Estimation of absolute risk for prostate cancer using genetic markers and family history , 2009, The Prostate.

[489]  Marshall W. Anderson,et al.  Cumulative Effect of Multiple Loci on Genetic Susceptibility to Familial Lung Cancer , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[490]  N. Mongan,et al.  Human androgen receptor gene ligand-binding-domain mutations leading to disrupted interaction between the N- and C-terminal domains. , 2006, Journal of molecular endocrinology.

[491]  P. Kufer,et al.  Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen , 2010, Cancer Immunology, Immunotherapy.

[492]  L. Aaltonen,et al.  Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. , 2004, Human molecular genetics.

[493]  Marshall W. Anderson,et al.  A susceptibility locus on chromosome 6q greatly increases lung cancer risk among light and never smokers. , 2010, Cancer research.

[494]  Lin Lin,et al.  Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. , 2009, Cancer cell.

[495]  M. Polette,et al.  Membrane-type metalloproteinases in tumor invasion. , 1998, The international journal of biochemistry & cell biology.

[496]  J. Byrd,et al.  Rituximab in B-cell chronic lymphocytic leukemia. , 2003, Seminars in oncology.

[497]  J. Trotter,et al.  AN2, the mouse homologue of NG2, is a surface antigen on glial precursor cells implicated in control of cell migration , 2002, Journal of neurocytology.

[498]  A. de la Chapelle,et al.  Hereditary Colorectal Cancer , 2010 .

[499]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[500]  W. Schulz,et al.  Epigenetic mechanisms in the biology of prostate cancer. , 2009, Seminars in cancer biology.

[501]  J. Wong,et al.  A role of the amino-terminal (N) and carboxyl-terminal (C) interaction in binding of androgen receptor to chromatin. , 2006, Molecular endocrinology.

[502]  Guillermo E. Rivas,et al.  Strong Signature of Natural Selection within an FHIT Intron Implicated in Prostate Cancer Risk , 2008, PloS one.

[503]  F. Collins,et al.  Evidence for a prostate cancer susceptibility locus on the X chromosome. , 1998, Nature Genetics.

[504]  S. Gruber,et al.  Pathologic Predictors of Microsatellite Instability in Colorectal Cancer , 2009, The American journal of surgical pathology.

[505]  A. Rosenthal,et al.  A novel repeat in the melanoma‐associated chondroitin sulfate proteoglycan defines a new protein family , 2002, FEBS letters.

[506]  S. Varambally,et al.  Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.

[507]  R. Kittles,et al.  NAT2 and NER genetic variants and sporadic prostate cancer susceptibility in African Americans , 2008, Prostate Cancer and Prostatic Diseases.

[508]  A. Nishiyama,et al.  Generation of truncated forms of the NG2 proteoglycan by cell surface proteolysis. , 1995, Molecular biology of the cell.

[509]  J. Herman,et al.  K-ras mutations and RASSF1A promoter methylation in colorectal cancer , 2002, Oncogene.

[510]  R. Shah,et al.  Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? , 2001, The American journal of pathology.

[511]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[512]  J. Parsons,et al.  Focal adhesion kinase: the first ten years , 2003, Journal of Cell Science.

[513]  The novel tumor‐suppressor Mel‐18 in prostate cancer: Its functional polymorphism, expression and clinical significance , 2009, International journal of cancer.

[514]  Erin E. Carlson,et al.  Dense genome-wide SNP linkage scan in 301 hereditary prostate cancer families identifies multiple regions with suggestive evidence for linkage. , 2009, Human molecular genetics.

[515]  M. Cooperberg,et al.  Active surveillance for the management of prostate cancer in a contemporary cohort , 2008, Cancer.

[516]  K Remberger,et al.  Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. , 1995, Human pathology.

[517]  X. Liu,et al.  Target Gene-specific Regulation of Androgen Receptor Activity by P42/p44 Mitogen-activated Protein Kinase , 2008 .

[518]  H. Pehamberger,et al.  Vaccination with a Human High Molecular Weight Melanoma-Associated Antigen Mimotope Induces a Humoral Response Inhibiting Melanoma Cell Growth In Vitro1 , 2005, The Journal of Immunology.

[519]  W. Bushman.  Etiology, epidemiology, and natural history of benign prostatic hyperplasia. , 2009, The Urologic clinics of North America.

[520]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[521]  M. O'brien,et al.  BRAF and KRAS Mutations in Hyperplastic Polyps and Serrated Adenomas of the Colorectum: Relationship to Histology and CpG Island Methylation Status , 2004, The American journal of surgical pathology.

[522]  E. J. Lee,et al.  Progressive methylation during the serrated neoplasia pathway of the colorectum , 2005, Modern Pathology.

[523]  R. Vij,et al.  Pro-urokinase-type Plasminogen Activator Is a Substrate for Hepsin* , 2006, Journal of Biological Chemistry.

[524]  C. Figdor,et al.  Characterization of melanoma‐associated surface antigens involved in the adhesion and motility of human melanoma cells , 1986, International journal of cancer.

[525]  M. J. C. Ludlam,et al.  Experimental Therapeutics , Molecular Targets , and Chemical Biology Pegylated Kunitz Domain Inhibitor Suppresses Hepsin-Mediated Invasive Tumor Growth and Metastasis , 2009 .

[526]  C. Heldin,et al.  Interaction between NG2 proteoglycan and PDGF α‐receptor on O2A progenitor cells is required for optimal response to PDGF , 1996, Journal of neuroscience research.

[527]  P. Nelson,et al.  Persistent intraprostatic androgen concentrations after medical castration in healthy men. , 2006, The Journal of clinical endocrinology and metabolism.

[528]  V. Quaranta,et al.  Laminin-332 Is a Substrate for Hepsin, a Protease Associated with Prostate Cancer Progression* , 2008, Journal of Biological Chemistry.

[529]  Ying Wang,et al.  A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. , 2009, American journal of human genetics.

[530]  Hans Clevers,et al.  Crypt stem cells as the cells-of-origin of intestinal cancer , 2009, Nature.

[531]  A. Kristal,et al.  Brassica Vegetables and Prostate Cancer Risk: A Review of the Epidemiological Evidence , 2002 .

[532]  B. Helfand,et al.  Established medical therapy for benign prostatic hyperplasia. , 2009, The Urologic clinics of North America.

[533]  F. Ruggiero,et al.  The Membrane-spanning Proteoglycan NG2 Binds to Collagens V and VI through the Central Nonglobular Domain of Its Core Protein* , 1997, The Journal of Biological Chemistry.

[534]  G. Wilson,et al.  In vivo targeting of malignant melanoma by 125Iodine- and 99mTechnetium-labeled single-chain Fv fragments against high molecular weight melanoma-associated antigen. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[535]  T. Mustelin,et al.  Phosphorylation of NG2 Proteoglycan by Protein Kinase C-α Regulates Polarized Membrane Distribution and Cell Motility* , 2004, Journal of Biological Chemistry.

[536]  Y. Samuels,et al.  Oncogenic mutations of PIK3CA in human cancers. , 2004, Current topics in microbiology and immunology.

[537]  Peter A. Jones,et al.  Locus-Wide Chromatin Remodeling and Enhanced Androgen Receptor-Mediated Transcription in Recurrent Prostate Tumor Cells , 2006, Molecular and Cellular Biology.

[538]  S. Lowe,et al.  Apoptosis and melanoma chemoresistance , 2003, Oncogene.

[539]  M. Lupien,et al.  Cistromics of hormone-dependent cancer. , 2009, Endocrine-related cancer.

[540]  F. Watt,et al.  Role of melanoma chondroitin sulphate proteoglycan in patterning stem cells in human interfollicular epidermis , 2003, Development.

[541]  D. Barritt,et al.  Cytoskeletal reorganization induced by engagement of the NG2 proteoglycan leads to cell spreading and migration. , 1999, Molecular biology of the cell.

[542]  W. Gerald,et al.  Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study , 2005, Modern Pathology.

[543]  T. Graeber,et al.  Myc-driven murine prostate cancer shares molecular features with human prostate tumors. , 2003, Cancer cell.

[544]  G. Cunha,et al.  Assessment of prostatic protein secretion in tissue recombinants made of urogenital sinus mesenchyme and urothelium from normal or androgen-insensitive mice. , 1993, Endocrinology.

[545]  D. Altshuler,et al.  Genetic Variation in the HSD17B1 Gene and Risk of Prostate Cancer , 2005, PLoS genetics.

[546]  J. Carpten,et al.  Chromosome 8q24 risk variants in hereditary and non‐hereditary prostate cancer patients , 2008, The Prostate.

[547]  J. Yokota,et al.  Contribution of nicotine acetylcholine receptor polymorphisms to lung cancer risk in a smoking-independent manner in the Japanese. , 2009, Carcinogenesis.

[548]  G. Schuler,et al.  Melanoma‐associated chondroitin sulphate proteoglycan as a new target antigen for CD4+ T cells in melanoma patients , 2009, International journal of cancer.

[549]  S. Loening,et al.  Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. , 2004, The Journal of urology.

[550]  E. Pasquale,et al.  The multi‐PDZ domain protein MUPP1 is a cytoplasmic ligand for the membrane‐spanning proteoglycan NG2 , 2000, Journal of cellular biochemistry.

[551]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[552]  P. Walsh,et al.  Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. , 2001, The Journal of urology.

[553]  Carla Oliveira,et al.  Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours , 2009, Human molecular genetics.

[554]  M. Herlyn,et al.  Melanoma Chondroitin Sulfate Proteoglycan Regulates Matrix Metalloproteinase-dependent Human Melanoma Invasion into Type I Collagen* , 2001, The Journal of Biological Chemistry.

[555]  Irving L. Weissman,et al.  Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271 , 2011, Nature.

[556]  Tomoaki Tanaka,et al.  Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor. , 2004, Oncology reports.

[557]  Robert A Gardiner,et al.  Use of multiple biomarkers for a molecular diagnosis of prostate cancer , 2005, International journal of cancer.

[558]  Jianfeng Xu,et al.  Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer , 2003, The Prostate.

[559]  M. Shen,et al.  Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. , 2006, Cancer research.

[560]  S. Farrington,et al.  Prognosis in DNA Mismatch Repair Deficient Colorectal Cancer: are all MSI Tumours Equivalent? , 2004, Familial Cancer.

[561]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[562]  J. Nicolas,et al.  Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. , 2002, Biochemistry.

[563]  M. Oberholzer,et al.  Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. , 1979, The Journal of urology.

[564]  Jae K Lee,et al.  Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. , 2008, Cancer research.

[565]  Antony W Burgess,et al.  Epidermal growth factor receptor: mechanisms of activation and signalling. , 2003, Experimental cell research.

[566]  S. Yeh,et al.  Tumor suppressor PAX6 functions as androgen receptor Co‐repressor to inhibit prostate cancer growth , 2010, The Prostate.

[567]  D. Cheresh,et al.  Human tumor antigens. , 1987, Advances in immunology.

[568]  M. Loda,et al.  The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer? , 2002, Cancer cell.

[569]  S. Song,et al.  Analysis of microsatellite instability, protein expression and methylation status of hMLH1 and hMSH2 genes in gastric carcinomas. , 2009, Hepato-gastroenterology.

[570]  Antoine H. F. M. Peters,et al.  LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription , 2005, Nature.

[571]  Zhiyong Guo,et al.  Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells , 2004, Oncogene.

[572]  J. Fukushi,et al.  NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. , 2004, Molecular biology of the cell.

[573]  K. Hemminki,et al.  MDM2 SNP309 and cancer risk: a combined analysis. , 2007, Carcinogenesis.

[574]  S. Weinstein,et al.  Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility , 2009, Proceedings of the National Academy of Sciences.

[575]  Narasimhan P. Agaram,et al.  Chordoma and chondrosarcoma gene profile: implications for immunotherapy , 2009, Cancer Immunology, Immunotherapy.

[576]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[577]  R. Matusik,et al.  Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[578]  S. Varambally,et al.  Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer , 2009, Science.

[579]  O. Klezovitch,et al.  Hepsin promotes prostate cancer progression and metastasis. , 2004, Cancer cell.

[580]  W. Isaacs,et al.  Human prostate cancer precursors and pathobiology. , 2003, Urology.

[581]  Ruth Etzioni,et al.  Effect of Population Trends in Body Mass Index on Prostate Cancer Incidence and Mortality in the United States , 2009, Cancer Epidemiology Biomarkers & Prevention.

[582]  M. Karin,et al.  Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. , 2010, Cytokine & growth factor reviews.

[583]  Stephan Huveneers,et al.  Adhesion signaling – crosstalk between integrins, Src and Rho , 2009, Journal of Cell Science.

[584]  S. Ferrone,et al.  Characterization of syngeneic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies. , 1989, Journal of immunology.

[585]  J. Herman,et al.  Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[586]  Leif E. Peterson,et al.  Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. , 2007, Cancer cell.

[587]  S. Holley,et al.  Associations Between G/A1229, A/G3944, T/C30875, C/T48200 and C/T65013 Genotypes and Haplotypes in the Vitamin D Receptor Gene, Ultraviolet Radiation and Susceptibility to Prostate Cancer , 2006, Annals of human genetics.

[588]  L. Miller,et al.  Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. , 1987, Cancer research.

[589]  Jianfeng Xu,et al.  Germ-line mutation of NKX3.1 cosegregates with hereditary prostate cancer and alters the homeodomain structure and function. , 2006, Cancer research.

[590]  Y. Takimoto,et al.  Fluorescence in situ hybridization analysis of c‐myc amplification in stage T3N0M0 prostate cancer in Japanese patients , 2006, International journal of urology : official journal of the Japanese Urological Association.

[591]  L. Fong,et al.  Therapeutic vaccines for prostate cancer. , 2010, Current opinion in molecular therapeutics.

[592]  R. Hofstra,et al.  Somatic mutations in mismatch repair genes in sporadic gastric carcinomas are not a cause but a consequence of the mutator phenotype. , 2008, Cancer genetics and cytogenetics.

[593]  Guillermo E. Rivas,et al.  Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHIT. , 2005, Cancer research.

[594]  D. Sargent,et al.  Clinical implications of microsatellite instability in sporadic colon cancers , 2009, Current opinion in oncology.

[595]  Jianfeng Xu,et al.  Association of Prostate-Specific Antigen Promoter Genotype with Clinical and Histopathologic Features of Prostate Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[596]  Christopher I Amos,et al.  Common 5p15.33 and 6p21.33 variants influence lung cancer risk , 2008, Nature Genetics.

[597]  U. Stein,et al.  Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. , 1994, Human pathology.

[598]  J. Kench,et al.  A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes , 2009, Oncogene.

[599]  G. Wilding,et al.  Androgen receptor requires JunD as a coactivator to switch on an oxidative stress generation pathway in prostate cancer cells. , 2010, Cancer research.

[600]  O. Jänne,et al.  Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. , 2004, Molecular endocrinology.

[601]  Poonam K Sharma,et al.  Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer , 2009, Familial Cancer.

[602]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[603]  S. Ferrone,et al.  Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibodies MK2-23. Experimental studies and clinical trials in patients with malignant melanoma. , 1993, Pharmacology & therapeutics.

[604]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[605]  F. Roviello,et al.  Evidence of tumor microsatellite instability in gastric cancer with familial aggregation , 2009, Familial Cancer.

[606]  J. Schalken,et al.  Epithelial cell differentiation in the human prostate epithelium: implications for the pathogenesis and therapy of prostate cancer. , 2003, Critical reviews in oncology/hematology.

[607]  T. Jacks,et al.  Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer , 2005, Cell.

[608]  M. Ranson,et al.  Plasminogen binding and cancer: promises and pitfalls. , 2003, Frontiers in bioscience : a journal and virtual library.

[609]  Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. , 2001, Molecular endocrinology.

[610]  S. Ferrone,et al.  Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. , 2004, Critical reviews in immunology.

[611]  P. Scardino,et al.  Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer , 2010, Clinical Cancer Research.

[612]  J. Ro,et al.  Prostatic intraepithelial neoplasia: recent advances. , 2009, Archives of pathology & laboratory medicine.